https://www.socictopen.socict.org/files/original/4afa8da7186c0875575bbc15e400a0a9.pdf 16edd00b67747589b261e57ceafd05b6 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Interferon-α2b Treatment for COVID-19 Creator An entity primarily responsible for making the resource Xu Wang, Zi-Hao Wang, Tobias R. Kollmann, Qiong Zhou, Scott J Tebbutt, Xiao-Shan Wei, Virginia Chen, Eleanor N Fish, Casey P. Shannon, Xuan Xiang Description An account of the resource The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-α2b should be further investigated as a therapy in COVID-19 cases. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource inflammation, IL-6, ARDS, interferon, viral shedding, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.3389/fimmu.2020.01061 Source A related resource from which the described resource is derived Frontiers in Immunology Publisher An entity responsible for making the resource available Frontiers Media S.A. Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Immunologic diseases. Allergy